Welcome to our dedicated page for Thermo Fisher Scientific news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fisher Scientific stock.
Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific (NYSE: TMO) reported Q1 2026 results: revenue grew 6% to $11.01 billion, GAAP diluted EPS rose 11% to $4.43, and adjusted EPS rose 6% to $5.44. Organic revenue growth was 1%. The company closed the Clario acquisition, repurchased $3.0 billion of stock, and raised the dividend by 10%. Management announced strategic collaborations with NVIDIA and SHL Medical and launched several new instruments and systems. Updated 2026 guidance will be provided on the earnings call held April 23, 2026.
Thermo Fisher Scientific (NYSE: TMO) announced a strategic collaboration with PRECISE to support the PRECISE-SG100K population biobank, deploying a combined proteomics strategy using Olink PEA, Orbitrap Astral mass spectrometry and Seer Proteograph to enable large-scale, high-sensitivity proteomic discovery and targeted measurement.
The program aims to strengthen reproducibility, support regulatory-grade evidence generation, and accelerate translational biomarker insights across Singapore’s diverse cohort; Thermo Fisher notes collective involvement in programs analyzing more than one million samples globally.
Thermo Fisher Scientific (NYSE: TMO) will release Q1 2026 financial results before the market opens on Thursday, April 23, 2026 and will host a conference call the same day at 8:30 a.m. ET.
The call will be webcast via the company website Investors section, with U.S. dial-in (833) 470-1428, international +1 (646) 844-6383 and access code 723173. A replay will be available through July 22, 2026.
Thermo Fisher Scientific (NYSE:TMO) completed the acquisition of Clario Holdings for $8.875 billion in cash, with an additional $125 million payable January 2027 and up to $400 million in performance-based earn-outs. The business joins Thermo Fisher's Laboratory Products and Biopharma Services segment and is expected to grow in the high single digits, be accretive to adjusted operating margin, and contribute $0.45 of adjusted EPS in the first year. Management expects approximately $175M of adjusted operating income from synergies by year five.
Clario’s platform has supported roughly 70% of FDA and EMA novel drug approvals over the past decade, enhancing Thermo Fisher’s clinical research data capabilities.
Thermo Fisher Scientific (NYSE: TMO) said its Board authorized a quarterly cash dividend of $0.47 per common share, payable April 15, 2026 to shareholders of record as of March 13, 2026. This represents a 10% increase from the prior quarterly dividend of $0.43.
Thermo Fisher Scientific (NYSE: TMO) said Marc N. Casper, chairman, president and CEO, will present at the Raymond James Institutional Investors Conference on March 3, 2026 at 9:15 a.m. ET. A live webcast will be available in the company's Investors section, with a replay accessible shortly after the presentation.
Thermo Fisher (NYSE: TMO) priced a $3.8 billion offering of USD-denominated senior notes across four maturities: $1.0B 4.215% due 2031, $750M 4.550% due 2033, $1.3B 4.902% due 2036, and $750M 5.546% due 2046.
The offering is expected to close on or about February 12, 2026, with semi-annual interest. Net proceeds are intended to pay part of the cash consideration for the pending Clario acquisition or for general corporate purposes pending closing.
Thermo Fisher Scientific (NYSE: TMO) reported Q4 2025 revenue of $12.21B (up 7%) and full-year 2025 revenue of $44.56B (up 4%).
GAAP diluted EPS was $5.21 for Q4 and $17.74 for the year; adjusted EPS was $6.57 Q4 and $22.87 for 2025. The company deployed $16.5B of capital in 2025, including $13B for M&A and returned $3.6B to shareholders.
Thermo Fisher Scientific (NYSE: TMO) announced a strategic collaboration with NVIDIA on January 12, 2026 to integrate NVIDIA AI infrastructure into Thermo Fisher instruments and lab software.
The partnership will use NVIDIA DGX Spark, NVIDIA NeMo and NVIDIA BioNeMo to add AI-driven automation, improve accuracy and speed workflows, connect instruments and data to AI models, and advance autonomous or “lab-in-the-loop” scientific workflows that aim to reduce manual steps and accelerate research.
Henry Schein (Nasdaq: HSIC) appointed Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026. Mr. Lowery will join the Board of Directors and succeeds Stanley M. Bergman, who will step down as CEO after 35 years and remain Chairman to support a leadership transition. Mr. Lowery brings more than two decades of healthcare distribution and operations experience, most recently serving as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher (NYSE: TMO). The appointment is presented as alignment with Henry Schein’s BOLD+1 strategic plan and aims to accelerate growth and value creation.